{"id":"W2083269457","doi":"10.1016/s1873-9954(08)70010-7","title":"9 ASSESSMENT OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF CROHN'S DISEASE IN PATIENTS FOR WHOM INFLIXIMAB TREATMENT WAS NOT SUCCESSFUL: OPEN-LABEL INDUCTION PRELIMINARY RESULTS FROM THE WELCOME STUDY","year":2008,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis Supplements","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Certolizumab pegol; Infliximab; Medicine; Crohn's disease; Open label; Adalimumab; Disease; Internal medicine; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003539937,0.0005761368,0.001822235,0.0002477626,0.0002742235,0.0009271398,0.0004321363,0.001647848,0.001591968],"category_scores_gemma":[0.005335669,0.0002420246,0.0009956316,0.0002211482,0.0006319481,0.0009275193,0.0003113413,0.002147931,0.0004660524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006175113,"about_ca_system_score_gemma":0.0005241797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000514398,"about_ca_topic_score_gemma":0.0009623854,"domain_scores_codex":[0.9981095,0.001251595,0.0001190009,0.0001670977,0.0002291092,0.0001237509],"domain_scores_gemma":[0.9946167,0.002663102,0.001149458,0.0003065891,0.0003286502,0.0009354975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7699925,0.006981524,0.03694488,0.0006502805,0.0009165236,0.0003776019,0.0002957332,0.0005429961,0.01321199,0.0001284222,0.001883203,0.1680742],"study_design_scores_gemma":[0.3916821,0.3872895,0.2008172,0.0003771462,0.001857898,0.001202018,0.0001994707,0.002728634,0.006612063,0.0004851177,0.006603263,0.0001455878],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841999,0.01153326,0.0004601596,0.001121194,0.0001462034,0.0003002915,0.0006637765,0.0000402406,0.001534947],"genre_scores_gemma":[0.9951164,0.001954635,0.0007825631,0.000488379,0.0002608054,0.0001882695,0.0006469928,0.0000127369,0.0005492229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003539937,"threshold_uncertainty_score":0.01872116,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06588458941485871,"score_gpt":0.3734134110423851,"score_spread":0.3075288216275264,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}